We are proud to announce that Shuk-Mei Ho, Ph.D., has accepted an invitation to serve on a Proposal Review Panel for the Office of Women’s Health (OWH) within the U.S. Food & Drug Administration (FDA), U.S. Department of Health & Human Services.
Dr. Ho’s appointment will run from September 14, 2026, through February 2027. During this appointment, the panel will evaluate grant and research proposals focused on evaluating cancer drug responses using advanced 3D organoid models, a critical area of study aimed at enhancing precision medicine and improving therapeutic outcomes in women’s oncology.
Please join us in congratulating Dr. Ho on this prestigious national appointment and her continued leadership in translational research!